1. ResMed has achieved double-digit revenue and profit growth over the past 9 years due to continuous acquisitions and improved operational efficiencies; 2. The company's capital efficiency showed mixed results with improvements in gross profitability and asset turnover, but a longer cash conversion cycle; 3. The company is financially sound, and there is a margin of safety if another major acquisition is assumed next year.
Related Articles
- Talkspace: Jumpstarting Momentum As Payor Programs Expand7 months ago
- Brookfield Corporation: A Slight Premium For A Generational Compounderabout 15 hours ago
- Meta's Valuation Doesn't Add Up2 months ago
- Lululemon Q4 2024 Earnings Update2 months ago
- Palantir: It's Like Nvidia In 2022 (Rating Upgrade)2 months ago
- Nvidia Is About To Explode: Buy The Dip Or Regret It Forever2 months ago
- The Unraveling Of DNA Company 23andMe2 months ago
- Grab: A Great International Diversification Play (Rating Upgrade)2 months ago
- Micron Q2: Anticipating More HBM Shipment In H23 months ago
- Nvidia: Why I Am Buying The Meltdown3 months ago